RxDoctor Payments DataLook up a doctor →

Venkata Gadi, MD

Interventional Cardiology · Baton Rouge, LANPI 1649451121

Payments from drug & device makers

$132,133in general payments, 2019–2025

Across 762 payments — averaging $173.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$47K
  • AstraZeneca$34K
  • Angiodynamics, Inc.$11K
  • Cardiovascular Systems Inc.$10K
  • Tryton Medical, Inc.$5K
  • Penumbra, Inc.$5K
  • plus $20K from 50 others

What the payments were for

  • Consulting fees$9001%
  • Speaking & faculty fees$64,58855%
  • Travel & lodging$19,30016%
  • Food & beverage$26,07822%
  • Education$1120%
  • Other$6,3805%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$132,133 in reported general payments places this provider in the 85th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$513,704
Medicare patients
494
Services billed
7,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$349,153
EntrestoSacubitril/Valsartan265$293,029
Repatha SureclickEvolocumab260$236,451
FarxigaDapagliflozin Propanediol233$204,338
XareltoRivaroxaban145$165,816
CamzyosMavacamten17$139,148
JardianceEmpagliflozin40$37,385
Praluent PenAlirocumab44$28,392
VascepaIcosapent Ethyl44$21,327
WegovySemaglutide14$20,221
Repatha PushtronexEvolocumab19$16,867
Ranolazine ErRanolazine136$13,995
Rosuvastatin Calcium1,125$12,850
NexletolBempedoic Acid14$11,283
NexlizetBempedoic Acid/Ezetimibe14$9,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$730$349,153318 claims
NovartisEntresto$549$293,029265 claims
AstraZenecaFarxiga$34,145$204,338233 claims
Johnson & JohnsonXarelto$1,006$165,816145 claims
E.r. Squibb & Sons, L.L.C.Camzyos$193$139,14817 claims
Boehringer IngelheimJardiance$199$37,38540 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$26$20,60728 claims
Novo NordiskWegovy$301$20,22114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →